PathoQuest
PathoQuest is a biotechnology company identifying pathogens through High Throughput Sequencing (HTS)..
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
* | €15.0m | Series B | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 763 % | 82 % | 102 % | 75 % | 13 % | 33 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (640 %) | (457 %) | (243 %) | (127 %) | (130 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (615 %) | (441 %) | (240 %) | (128 %) | (155 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
PathoQuest operates in the biologics sector, providing genomic services that focus on pathogen detection to enhance clinical decision-making. The company serves clients in the pharmaceutical and biotechnology industries, particularly those involved in cell and gene therapy products. PathoQuest's business model revolves around offering specialized testing services that ensure the safety and efficacy of biological drugs. By obtaining Pharmaceutical Establishment status from the French ANSM, PathoQuest has solidified its position in the market, allowing it to conduct comprehensive biological drug testing activities. The company generates revenue through service contracts with biopharma companies, aiming to improve the safety of biologics and accelerate their time to market. PathoQuest's participation in industry events like BioProcess International Europe and BioPharma Asia webinars highlights its commitment to staying at the forefront of viral safety and pathogen detection advancements.
Keywords: biologics, genomic services, pathogen detection, clinical decision-making, pharmaceutical, biotechnology, cell therapy, gene therapy, drug testing, viral safety